Skip to content Skip to footer
Subscribe Now
NEWS

Quotient Therapeutics & Merck Enter ~$2.2B Partnership to Discover Novel Drug Targets in IBD

Shots: Quotient has entered into a multi-year research collaboration agreement with Merck to discover novel drug targets in inflammatory bowel disease leveraging Quotient’s somatic genomics platform tech Through its somatic genomics platform, Quotient analyzes patient tissue to identify disease-causing or protective mutations, generating insights that inform novel therapeutic strategies across multiple conditions, including IBD As…
4 days ago

Read more

NEWS

Tenaya Therapeutics and Alnylam Pharmaceuticals Partner to Discover Novel Genetic Targets for CV Therapies in ~$1.13B Deal

Shots: Tenaya has entered into a research collaboration with Alnylam to identify novel human genetic targets that could enable the development of disease-modifying therapies for cardiovascular (CV) diseases Under the collaboration, Tenaya will validate up to 15 gene targets, while Alnylam will lead all the development & commercialization of therapies arising from these validated targets…
March 6, 2026

Read more

NEWS

Adaptive Biotechnologies and Pfizer Sign Rheumatoid Arthritis TCR Target Discovery and Immune Data Licensing Deals

Shots: Adaptive has entered into 2 non-exclusive agreements with Pfizer, combining its T-cell receptor (TCR) discovery & immune receptor antigen-mapping platform to support Pfizer’s research across autoimmune & other disease areas As per the target discovery deal, Adaptive will identify disease-specific TCR targets in rheumatoid arthritis from Pfizer clinical samples, while Pfizer will lead development…
December 16, 2025

Read more

NEWS

Novartis and Relation Therapeutics Ink ~$1.75B Atopic Disease Target-Discovery Alliance

Shots: Relation has entered into a multi-program, strategic collaboration with Novartis to identify & advance novel targets for atopic diseases, leveraging Relation’s Lab-in-the-Loop platform As per the deal, Relation will lead patient-derived observational studies to create high-resolution functional cell atlases, while Novartis will secure global development & commercialization rights to any resulting targets In return,…
December 10, 2025

Read more